Changes in the intraocular cytokine levels after intravitreal bevacizumab in uveitic macular edema

Ocul Immunol Inflamm. 2012 Oct;20(5):360-4. doi: 10.3109/09273948.2012.709576.

Abstract

Purpose: To evaluate the changes in intraocular cytokine after intravitreal bevacizumab (IVB) for uveitic cystoid macular edema (CME).

Methods: The authors evaluated 9 eyes of 8 patients who underwent IVB for uveitic CME. The aqueous humor-levels of vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β(2)were measured using suspension array technology at baseline and 1 month after IVB.

Results: The VEGF level was decreased to insignificant level (p = .008). TGF-β(2) and TNF-α levels increased significantly (p = .008 and .021, respectively). IL-6 and IL-8 showed no significant change (p = .051 and.110, respectively).

Conclusion: IVB resulted in a significant decrease of VEGF levels, which was associated with anatomical improvement of CME at 1 month. Compensatory elevations of proinflammatory cytokines (IL-6 and IL-8) after selective VEGF inhibition were not observed. Marked elevation of TGF-β(2) after IVB seems to play an immunosuppressive role.

MeSH terms

  • Adolescent
  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Aqueous Humor / chemistry
  • Aqueous Humor / drug effects
  • Bevacizumab
  • Cytokines / analysis
  • Cytokines / metabolism*
  • Female
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy*
  • Male
  • Middle Aged
  • Uveitis / drug therapy*
  • Young Adult

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Bevacizumab